Related Experiment Video
Updated: May 30, 2026
09:16
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Participant characteristics and buprenorphine dose
Maureen Hillhouse1, Catherine P Canamar, Geetha Doraimani
1UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA. hillhous@ucla.edu
The American Journal of Drug and Alcohol Abuse
|August 23, 2011
Summary
Buprenorphine dose in opioid dependence treatment varied based on patient characteristics. Higher doses were linked to increased opioid use, suggesting a need for personalized dosing strategies.
Area of Science:
- Addiction Medicine
- Pharmacotherapy
- Clinical Research
Background:
- Clinical parameters for buprenorphine dosing require further investigation in treatment outcome research.
- Understanding factors influencing optimal buprenorphine dosage is crucial for effective opioid dependence treatment.
Purpose of the Study:
- To analyze if participant baseline characteristics are associated with buprenorphine dose.
- Secondary analysis of data from a buprenorphine taper schedules study.
Main Methods:
- 516 participants were categorized by their final week buprenorphine dose (8 mg, 16 mg, or 24 mg) after 3 weeks of flexible dosing.
- Baseline demographic and drug use characteristics were compared across dose groups.
Main Results:
- Significant differences observed in education, heroin use, route of administration, withdrawal symptoms, and craving among dose groups.
- Higher buprenorphine doses (16 mg and 24 mg) were associated with greater continued opioid use compared to the 8 mg group (p < .0001).
Conclusions:
- Final buprenorphine dose groups exhibited distinct demographic and drug use profiles.
- The highest buprenorphine dose group showed the highest rate of continued opioid use, indicating potential implications for clinical guidelines.
- Further research with randomized dose assignment based on baseline characteristics is recommended.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...